NUS Links:
N2CR member, A/Prof Too Heng-Phon, Dr Sarah Ho and team have developed a way to use stem cells to treat cancer in cats and dogs, a method originally developed for
Precision Cancer Medicine thematic member, Dr Yong Wei Peng was part of a team who developed an antibody-drug conjugate (ADC), the first of its kind to be created in Singapore.
A/Prof Koh Liang Piu, member of the N2CR Tissue-Specific Carcinogenesis theme, helped to develop a cell selection technique that gives blood cancer patients a higher chance of finding a match
(image credit: The Straits Times) For the past two decades, Prof Too has played a tremendous role in strengthening life sciences research and development in Singapore. His steadfast dedication
Every year, analytics company Clarivate publishes a list of highly cited researchers who have constantly produced high impact research and published multiple highly cited papers in the last decade. This
Every year Stanford University publishes a list of highly cited scientists based on citation metrics from Scopus. The list for the citation year 2021 is accessible here: https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/4 A huge
N2CR member Associate Professor Too Heng-Phon, who co-foundered biotech firm MiRXES with two of his former PhD students, Dr Zhou Lihan and Dr Zhou Ruiyang, has developed a test kit
N2CR members, A/Prof Edward Chow and Dr Anand Jeyasekharan have found a method to create a more personalized combination of drugs for their cancer patients. Both doctors, who are principal
Two N2CR members, A/Prof Glenn Bonney and Dr. Raghav Sundar were part of the surgical team who conducted a living donor liver transplant on Mdm Lim, a patient with stage
N2CR had the privilege of helping to host the Joint NUS ncRNA Symposium and Liquid Biopsy Summit from 20 – 22 September 2022. A joint effort between NUS Medicine,